Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects

Andrea Giacomelli, Alice Ranzani, Letizia Oreni, Elena Gervasi, Angelica Lupo, Anna Lisa Ridolfo, Massimo Galli, Stefano RusconiIII Infectious Disease Unit, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, ItalyPurpose: Integrase inhibitor (INI)-contai...

Full description

Bibliographic Details
Main Authors:	Giacomelli A, Ranzani A, Oreni L, Gervasi E, Lupo A, Ridolfo AL, Galli M, Rusconi S
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-07-01
Series:	Drug Design, Development and Therapy
Subjects:	HIV protease inhibitors integrase inhibitors dolutegravir lipids Framingham
Online Access:	https://www.dovepress.com/durability-of-ini-containing-regimens-after-switching-from-pi-containi-peer-reviewed-article-DDDT

Similar Items

Modern antiretroviral regimens
by: A. V. Kravchenko
Published: (2016-12-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01)

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana
by: Kaelo K. Seatla, et al.
Published: (2021-03-01)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
by: Raffi Francois, et al.
Published: (2012-12-01)

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study
by: Andrea Giacomelli, et al.
Published: (2021-06-01)

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020-09-01)

Are new antiretroviral treatments increasing the risks of clinical obesity?
by: Andrew Hill, et al.
Published: (2019-01-01)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
by: Yuanlu Shu, et al.
Published: (2021-05-01)

Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
by: Eugenia Bruzzese, et al.
Published: (2018-03-01)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
by: Joseph Fokam, et al.
Published: (2020-08-01)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
by: Lucia Taramasso, et al.
Published: (2018-07-01)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
by: Collins C. Iwuji, et al.
Published: (2020-07-01)

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety
by: Valeria Cento, et al.
Published: (2020-03-01)

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
by: Aleksey Viktorovich Kravchenko, et al.
Published: (2010-11-01)

HIVprotI: an integrated web based platform for prediction and design of HIV proteins inhibitors
by: Abid Qureshi, et al.
Published: (2018-03-01)

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
by: Stephan C, et al.
Published: (2010-09-01)

Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis
by: Ke Zhang, et al.
Published: (2021-07-01)

How can we achieve universal access to low-cost treatment for HIV?
by: Andrew M. Hill, et al.
Published: (2016-10-01)

<b>Functionalization of Nitrogen-Containing Heterocycles in the Synthesis of Biologically Active Molecules</b>
by: Patel, Pratiq A.
Published: (2013)

Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen
by: Kuritzkes Daniel R, et al.
Published: (2005-04-01)

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol
by: Ezechiel Ngoufack Jagni Semengue, et al.
Published: (2020-04-01)

Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals
by: Pablo López, et al.
Published: (2021-03-01)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
by: Thibault Mesplède, et al.
Published: (2015-07-01)

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
by: Thibault Mesplède, et al.
Published: (2014-08-01)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01)

Novel therapeutic strategies targeting HIV integrase
by: Quashie Peter K, et al.
Published: (2012-04-01)

Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting
by: Mehari EA, et al.
Published: (2021-06-01)

Generation of soluble, catalytically active covalent HIV-1 subtype C integrase-DNA complexes to identify novel strand transfer inhibitors
by: Beyleveld, Grant James
Published: (2014)

Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen
by: Jean Michel Petit, et al.
Published: (2003-09-01)

Resistance to inhibitors of the human immunodeficiency virus type 1 integration
by: Daria J Hazuda

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
by: Amedeo F. Capetti, et al.
Published: (2017-09-01)

Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports
by: Takefumi Suzuki, et al.
Published: (2017-09-01)

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection
by: Abbate, I., et al.
Published: (2022)

Research progress in anti-HCV therapeutic regimens without interferon
by: LI Qiang, et al.
Published: (2016-01-01)

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
by: Bonfanti P, et al.
Published: (2020-07-01)

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
by: Adetayo Emmanuel Obasa, et al.
Published: (2020-03-01)

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity
by: Céline Amadori, et al.
Published: (2017-11-01)